ProMIS Neurosciences Inc. PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared To Other Amyloid-Beta-Directed Antibodies In Poster Presentation At AD/PD 2023
ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as